Clinical Trial Update: Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial updating the safety, tolerability, and pharmacodynamic effects of FRM-0334 in individuals with frontotemporal dementia due to granulin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontotemporal Dementia

Drugs mentioned

• FRM-0334

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Granulin Mutation | Phase 2 | Status: UNKNOWN